Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids.
Conservative surgical options for uterine myomata traditionally were abdominal myomectomy, laparoscopic myomectomy, and, more recently, myolysis. Each of these procedures has distinct advantages, but also apparent disadvantages. We attempted to introduce an additional option for conservative surgical treatment of fibroids by freezing the structures, a procedure termed cryomyolysis. In this pilot study, 14 women were pretreated with a gonadotropin-releasing hormone (GnRH) agonist for a minimum of 2 months preoperatively to minimize uterine and myoma size. Cryomyolysis was performed and the GnRH agonist was discontinued. Magnetic resonance imaging scans were performed in 10 of the 14 women after GnRH agonist treatment but before surgery, and 4 months postoperatively. Total uterine volume ranged from 41.3 to 1134.8 ml preoperatively, and 49.5 to 1320 ml postoperatively (mean increase 22% after discontinuation of GnRH agonist). Normal uterine volume ranged from 35.6 to 548.7 ml preoperatively and 45.1 to 729.6 ml postoperatively (mean increase 40%); however, myoma volume showed a mean decrease of 6% (range -87-28%). Analysis of only frozen myomata revealed a mean volume decrease of 10%. Cryomyolysis maintains at or slightly reduces these lesions to post-GnRH agonist size, and all other uterine tissue returns to pretreatment size. We believe cryomyolysis may be an effective conservative surgical approach to uterine fibroids.
Zreik
T G
TG
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Yale University School of Medicine, P.O. Box 208063, New Haven, CT 06520-8063, USA.
Rutherford
T J
TJ
Palter
S F
SF
Troiano
R N
RN
Williams
E
E
Brown
J M
JM
Olive
D L
DL
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003452:Cryosurgery / Q000379:methods*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D010535:Laparoscopy / Q000379:methods*; D007889:Leiomyoma / Q000601:surgery*; D016729:Leuprolide / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D010865:Pilot Projects; D011292:Premedication; D011446:Prospective Studies; D014594:Uterine Neoplasms / Q000601:surgery*; D014599:Uterus / Q000473:pathology / Q000601:surgery
D018931:Antineoplastic Agents, Hormonal; D016729:Leuprolide